Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WW domain binding protein VOPP1 (VOPP1) is a protein coding gene implicated in cancer, most notably glioblastoma and breast carcinoma[1][6]. VOPP1 increases the transcriptional activity of the nuclear factor kappa B subunit 1 (NFKB1) by facilitating its nuclear translocation, DNA-binding, and associated apoptotic response, especially when overexpressed[4][5][7]. It is proposed to sequester the tumor suppressor WWOX in lysosomal vesicles, thereby regulating WWOX’s tumor-suppressive activity[1]. Subcellularly, VOPP1 localizes to the cytoplasmic vesicle membrane, late endosome, and lysosome[3]. There is not a direct small-molecule or biologic targeting VOPP1 in clinical use, but its involvement in NFKB signaling and oncogenesis makes it a potential target of interest for drug discovery in cancer therapy[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WW domain binding protein VOPP1 (VOPP1).